

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/024074-2024>

Planning

Supply of Classical Swine Fever (CSF) Vaccine

Defra Network eTendering Portal

F01: Prior information notice

Prior information only

Notice identifier: 2024/S 000-024074

Procurement identifier (OCID): ocids-h6vhtk-04869c

Published 1 August 2024, 9:58am

Section I: Contracting authority

I.1) Name and addresses

Defra Network eTendering Portal

Seacole Building, 2 Marsham Street

London

SW1P 4DF

Contact

Melanie Swain

Email

melanie.swain@defra.gov.uk

Country

United Kingdom

Region code

UK - United Kingdom

Internet address(es)

Main address

<https://www.gov.uk/government/organisations/department-for-environment-food-rural-affairs>

Buyer's address

<https://defra-family.force.com/s/Welcome>

I.3) Communication

Additional information can be obtained from the above-mentioned address

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

Environment

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Supply of Classical Swine Fever (CSF) Vaccine

Reference number

P-36219

II.1.2) Main CPV code

- 33651690 - Vaccines for veterinary medicine

II.1.3) Type of contract

Supplies

II.1.4) Short description

The Authority is seeking to identify existing and potential suppliers of Classical Swine Fever vaccine who have products with robust evidence of quality, safety, and efficacy. We are keen to hear from suppliers who are in a position to supply suitable Classical Swine Fever vaccine products to the UK vaccine bank as early as March 2025.

The Authority is specifically interested in:

- Vaccines against Classical Swine Fever.
- The efficacy and period (onset and duration) of immunity in pigs (Suids).
- Safety data in pigs (Suids).
- The proposed number of doses in the vaccination schedule.
- Storage conditions.
- Any information that might be provided about potential cost.
- Whether the vaccine is or will be manufactured under the conditions of Good Manufacturing Practice (GMP).
- Whether quality aspects are considered such that the vaccine is manufactured and stored according to the WOAHP Terrestrial Manual Chapter 3.9.3.
- Whether the product has DIVA capabilities.
- Whether the vaccine can be used in wildlife.

The Authority is seeking this information to inform decisions around guarantees of supply to the UK market. An estimated total value is therefore not provided at this stage.

II.1.5) Estimated total value

Value excluding VAT: £1

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Authority is exploring options for supply of vaccines to the UK Classical Swine Fever Vaccine Bank, for delivery by 28 March 2025. If a decision is taken to renew the vaccine bank for CSF, vaccine products must be available for use by the Authority from the commencement of any contract, either as an authorised product or for emergency use under Schedule 4 of the Veterinary Medicines Regulations 2013 (as amended). This could be as early as April 2025. The Authority will consider products which have good evidence of quality, safety, and efficacy.

The Authority is interested in:

- The details of CSF vaccine products.
- Number and size of dose.
- Data on safety and efficacy.
- Data on the onset and duration of immunity.
- Storage conditions and bottle sizes available.
- The type of technology used to develop the vaccine.
- Production capacity.
- Species that can be vaccinated and any data on the minimum age that animals can be vaccinated.
- Whether the vaccine is produced to GMP standard.
- Whether the vaccine is manufactured and stored according to the WOAHP Terrestrial Manual Chapter 3.9.3.
- Whether the vaccine is currently authorised for use with a valid marketing authorisation, and if so where is the vaccine authorised.
- Whether the vaccine has been used elsewhere in the world under permit rather than as an authorised vaccine.

- Whether the vaccine has DIVA capabilities.
- Whether it can be used in wildlife and whether different formulations for use in baits are available.
- Timelines for submitting applications for a marketing authorisation to VMD (if relevant).
- The likely cost of the product.

II.2.14) Additional information

This Prior Information Notice (PIN) is not a call for competition. It should be noted that this PIN invites individuals and organisations to express an interest only, and although it is not part of a formal pre-qualification process it may be used to inform discussions with vaccine suppliers.

You will need to express your interest in any potential future tender opportunity once / if a Contract Notice is published in Find a Tender and on Contracts Finder. It should be noted that this PIN invites individuals and organisations to express an interest only. Those wishing to provide information requested here should contact Melanie Swain (melanie.swain@defra.gov.uk) by the 23rd August 2024 to inform our strategy development.

II.3) Estimated date of publication of contract notice

31 October 2024

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes